A new macromolecular paramagnetic MR contrast agent binds to activated human platelets

Fréderic Chaubet, Isabelle Bertholon, Jean Michel Serfaty, Ramin Bazeli, Hasan Alsaid, Martine Jandrot-Perrus, Charaf Zahir, Pascale Even, Laure Bachelet, Ziad Touat, Eric Lancelot, Claire Corot, Emmanuelle Canet-Soulas, Didier Letourneur

Research output: Contribution to journalArticle

Abstract

A new functionalized macromolecular magnetic resonance (MR) contrast agent has been developed from a carboxymethyldextran-Gd(DOTA) devoid of biospecificity. The functionalized contrast agent was synthesized in order to mimic PSGL-1, the main ligand of P-selectin, a glycoprotein mainly expressed on the surface of activated platelets. The starting compound, CM1, was first carboxymethylated by monochloroacetic acid leading to a series of 10 derivatives varying in their carboxymethyl content. CM8 derivative, with a degree of substitution in carboxymethyl of 0.84, was chosen for subsequent fluorolabeling and sulfation to give CM8FS. CM8FS has an average number molecular weight of 27 000 ± 500 g/ mol, a hydrodynamic radius of 5.7 ± 0.2 nm and a high relaxivity (r1 = 11.2/mM (Gd)/s at 60 MHz). Flow cytometry experiments on whole human blood or on isolated platelets evidenced in vitro a preferential binding of CM8FS on TRAP-activated human platelets. Interestingly, CMSFS did not bind to other blood cells or to resting platelets. Pellets of TRAP-activated human platelets have also been imaged in tubes with a 1.5 T MR imager. A MR signal was observed for activated platelets incubated with CMSFS. Altogether, these in vitro results evidenced the recognition of activated human platelets by a fluorescent paramagnetic contrast agent grafted with carboxyl and sulfate groups. This biomimetic approach associated with the versatile macromolecular platform appears promising for the development of new contrast agents for molecular imaging of activated platelets in cardiovascular diseases such as atherosclerosis and aneurysms.

Original languageEnglish (US)
Pages (from-to)178-188
Number of pages11
JournalContrast Media and Molecular Imaging
Volume2
Issue number4
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Electron Spin Resonance Spectroscopy
Contrast Media
Magnetic Resonance Spectroscopy
Blood Platelets
Biomimetics
Molecular Imaging
P-Selectin
Hydrodynamics
Sulfates
Aneurysm
Blood Cells
Atherosclerosis
Glycoproteins
Flow Cytometry
Cardiovascular Diseases
Molecular Weight
Ligands

Keywords

  • Activated platelets
  • Atherosclerosis
  • Contrast agent
  • Flow cytometry
  • Gadolinium
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Chaubet, F., Bertholon, I., Serfaty, J. M., Bazeli, R., Alsaid, H., Jandrot-Perrus, M., ... Letourneur, D. (2007). A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. Contrast Media and Molecular Imaging, 2(4), 178-188. https://doi.org/10.1002/cmmi.144

A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. / Chaubet, Fréderic; Bertholon, Isabelle; Serfaty, Jean Michel; Bazeli, Ramin; Alsaid, Hasan; Jandrot-Perrus, Martine; Zahir, Charaf; Even, Pascale; Bachelet, Laure; Touat, Ziad; Lancelot, Eric; Corot, Claire; Canet-Soulas, Emmanuelle; Letourneur, Didier.

In: Contrast Media and Molecular Imaging, Vol. 2, No. 4, 07.2007, p. 178-188.

Research output: Contribution to journalArticle

Chaubet, F, Bertholon, I, Serfaty, JM, Bazeli, R, Alsaid, H, Jandrot-Perrus, M, Zahir, C, Even, P, Bachelet, L, Touat, Z, Lancelot, E, Corot, C, Canet-Soulas, E & Letourneur, D 2007, 'A new macromolecular paramagnetic MR contrast agent binds to activated human platelets', Contrast Media and Molecular Imaging, vol. 2, no. 4, pp. 178-188. https://doi.org/10.1002/cmmi.144
Chaubet F, Bertholon I, Serfaty JM, Bazeli R, Alsaid H, Jandrot-Perrus M et al. A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. Contrast Media and Molecular Imaging. 2007 Jul;2(4):178-188. https://doi.org/10.1002/cmmi.144
Chaubet, Fréderic ; Bertholon, Isabelle ; Serfaty, Jean Michel ; Bazeli, Ramin ; Alsaid, Hasan ; Jandrot-Perrus, Martine ; Zahir, Charaf ; Even, Pascale ; Bachelet, Laure ; Touat, Ziad ; Lancelot, Eric ; Corot, Claire ; Canet-Soulas, Emmanuelle ; Letourneur, Didier. / A new macromolecular paramagnetic MR contrast agent binds to activated human platelets. In: Contrast Media and Molecular Imaging. 2007 ; Vol. 2, No. 4. pp. 178-188.
@article{51bfcd251c4f47c4a6bc9bfdc003e6f8,
title = "A new macromolecular paramagnetic MR contrast agent binds to activated human platelets",
abstract = "A new functionalized macromolecular magnetic resonance (MR) contrast agent has been developed from a carboxymethyldextran-Gd(DOTA) devoid of biospecificity. The functionalized contrast agent was synthesized in order to mimic PSGL-1, the main ligand of P-selectin, a glycoprotein mainly expressed on the surface of activated platelets. The starting compound, CM1, was first carboxymethylated by monochloroacetic acid leading to a series of 10 derivatives varying in their carboxymethyl content. CM8 derivative, with a degree of substitution in carboxymethyl of 0.84, was chosen for subsequent fluorolabeling and sulfation to give CM8FS. CM8FS has an average number molecular weight of 27 000 ± 500 g/ mol, a hydrodynamic radius of 5.7 ± 0.2 nm and a high relaxivity (r1 = 11.2/mM (Gd)/s at 60 MHz). Flow cytometry experiments on whole human blood or on isolated platelets evidenced in vitro a preferential binding of CM8FS on TRAP-activated human platelets. Interestingly, CMSFS did not bind to other blood cells or to resting platelets. Pellets of TRAP-activated human platelets have also been imaged in tubes with a 1.5 T MR imager. A MR signal was observed for activated platelets incubated with CMSFS. Altogether, these in vitro results evidenced the recognition of activated human platelets by a fluorescent paramagnetic contrast agent grafted with carboxyl and sulfate groups. This biomimetic approach associated with the versatile macromolecular platform appears promising for the development of new contrast agents for molecular imaging of activated platelets in cardiovascular diseases such as atherosclerosis and aneurysms.",
keywords = "Activated platelets, Atherosclerosis, Contrast agent, Flow cytometry, Gadolinium, Magnetic resonance imaging",
author = "Fr{\'e}deric Chaubet and Isabelle Bertholon and Serfaty, {Jean Michel} and Ramin Bazeli and Hasan Alsaid and Martine Jandrot-Perrus and Charaf Zahir and Pascale Even and Laure Bachelet and Ziad Touat and Eric Lancelot and Claire Corot and Emmanuelle Canet-Soulas and Didier Letourneur",
year = "2007",
month = "7",
doi = "10.1002/cmmi.144",
language = "English (US)",
volume = "2",
pages = "178--188",
journal = "Contrast Media and Molecular Imaging",
issn = "1555-4309",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - A new macromolecular paramagnetic MR contrast agent binds to activated human platelets

AU - Chaubet, Fréderic

AU - Bertholon, Isabelle

AU - Serfaty, Jean Michel

AU - Bazeli, Ramin

AU - Alsaid, Hasan

AU - Jandrot-Perrus, Martine

AU - Zahir, Charaf

AU - Even, Pascale

AU - Bachelet, Laure

AU - Touat, Ziad

AU - Lancelot, Eric

AU - Corot, Claire

AU - Canet-Soulas, Emmanuelle

AU - Letourneur, Didier

PY - 2007/7

Y1 - 2007/7

N2 - A new functionalized macromolecular magnetic resonance (MR) contrast agent has been developed from a carboxymethyldextran-Gd(DOTA) devoid of biospecificity. The functionalized contrast agent was synthesized in order to mimic PSGL-1, the main ligand of P-selectin, a glycoprotein mainly expressed on the surface of activated platelets. The starting compound, CM1, was first carboxymethylated by monochloroacetic acid leading to a series of 10 derivatives varying in their carboxymethyl content. CM8 derivative, with a degree of substitution in carboxymethyl of 0.84, was chosen for subsequent fluorolabeling and sulfation to give CM8FS. CM8FS has an average number molecular weight of 27 000 ± 500 g/ mol, a hydrodynamic radius of 5.7 ± 0.2 nm and a high relaxivity (r1 = 11.2/mM (Gd)/s at 60 MHz). Flow cytometry experiments on whole human blood or on isolated platelets evidenced in vitro a preferential binding of CM8FS on TRAP-activated human platelets. Interestingly, CMSFS did not bind to other blood cells or to resting platelets. Pellets of TRAP-activated human platelets have also been imaged in tubes with a 1.5 T MR imager. A MR signal was observed for activated platelets incubated with CMSFS. Altogether, these in vitro results evidenced the recognition of activated human platelets by a fluorescent paramagnetic contrast agent grafted with carboxyl and sulfate groups. This biomimetic approach associated with the versatile macromolecular platform appears promising for the development of new contrast agents for molecular imaging of activated platelets in cardiovascular diseases such as atherosclerosis and aneurysms.

AB - A new functionalized macromolecular magnetic resonance (MR) contrast agent has been developed from a carboxymethyldextran-Gd(DOTA) devoid of biospecificity. The functionalized contrast agent was synthesized in order to mimic PSGL-1, the main ligand of P-selectin, a glycoprotein mainly expressed on the surface of activated platelets. The starting compound, CM1, was first carboxymethylated by monochloroacetic acid leading to a series of 10 derivatives varying in their carboxymethyl content. CM8 derivative, with a degree of substitution in carboxymethyl of 0.84, was chosen for subsequent fluorolabeling and sulfation to give CM8FS. CM8FS has an average number molecular weight of 27 000 ± 500 g/ mol, a hydrodynamic radius of 5.7 ± 0.2 nm and a high relaxivity (r1 = 11.2/mM (Gd)/s at 60 MHz). Flow cytometry experiments on whole human blood or on isolated platelets evidenced in vitro a preferential binding of CM8FS on TRAP-activated human platelets. Interestingly, CMSFS did not bind to other blood cells or to resting platelets. Pellets of TRAP-activated human platelets have also been imaged in tubes with a 1.5 T MR imager. A MR signal was observed for activated platelets incubated with CMSFS. Altogether, these in vitro results evidenced the recognition of activated human platelets by a fluorescent paramagnetic contrast agent grafted with carboxyl and sulfate groups. This biomimetic approach associated with the versatile macromolecular platform appears promising for the development of new contrast agents for molecular imaging of activated platelets in cardiovascular diseases such as atherosclerosis and aneurysms.

KW - Activated platelets

KW - Atherosclerosis

KW - Contrast agent

KW - Flow cytometry

KW - Gadolinium

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=35148887221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148887221&partnerID=8YFLogxK

U2 - 10.1002/cmmi.144

DO - 10.1002/cmmi.144

M3 - Article

C2 - 17828728

AN - SCOPUS:35148887221

VL - 2

SP - 178

EP - 188

JO - Contrast Media and Molecular Imaging

JF - Contrast Media and Molecular Imaging

SN - 1555-4309

IS - 4

ER -